{"nctId":"NCT04048343","briefTitle":"Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma","startDateStruct":{"date":"2019-06-10","type":"ACTUAL"},"conditions":["Severe Asthma"],"count":65,"armGroups":[{"label":"Tezepelumab","type":"EXPERIMENTAL","interventionNames":["Drug: Biological: Experimental: Tezepelumab"]}],"interventions":[{"name":"Biological: Experimental: Tezepelumab","otherNames":["Tezepelumab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAge. 12-80 Documented physician-diagnosed asthma for at least 12 months Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.\n\nDocumented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.\n\nAt least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.\n\nDocumented history of at least 1 asthma exacerbation events within 12 months. ACQ-6 score ≥1.5 at screening or on day of registration.\n\nExclusion Criteria:\n\nPulmonary disease other than asthma. History of cancer. History of a clinically significant infection. Current smokers or subjects with smoking history ≥10 pack-yrs. History of chronic alcohol or drug abuse within 12 months. Hepatitis B, C or HIV. Pregnant or breastfeeding. History of anaphylaxis following any biologic therapy. Subject randomized in the current study or previous tezepelumab studies","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Adverse Events","description":"The number of subjects who experienced an AE during on-treatment period was summarised.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["Nasopharyngitis","Pharyngitis","Herpes zoster","Contusion","Back pain"]}}}